Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...

Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve ...

Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

U.S.-based pharmaceutical giant German biotech company BioNTech were already collaborating to come up with a flu vaccine ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Coronavirus disease (COVID-19) vaccination campaign in Ronda LONDON (Reuters) -Pfizer and its German partner BioNTech ...

A messenger RNA combination vaccine that Pfizer and BioNTech are developing for both Covid-19 and influenza posted mixed results in a pivotal study, meeting just one of the two main goals assessing ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently fell behind in their race with Moderna (NASDAQ: MRNA) to develop new combination shots that could be worth billions in annual sales. Top-line ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...